Tissue-engineered fascia from vaginal fibroblasts for patientsneeding reconstructive pelvic surgery
Tissue-engineered fascia from vaginal fibroblasts for patientsneeding reconstructive pelvic surgery
复制标题
DOI：
10.1007/s00192-010-1168-3
复制
发表时间：
2010-09-01
影响因子：
1.8
通讯作者：
Yang, Vivian Cheng
中科院分区：
文献类型：
--
作者：
Hung, Man-Jung;Wen, Mei-Chin;Yang, Vivian Cheng
盆腔器官脱垂的网格增强重建手术（POP）不能满足临床期望。需要开发一种组织工程筋膜等效物。对10例患者的阴道成纤维细胞（HVFs）进行了体外鉴定。使用合适的HVFs和可生物降解的支架来制造等效的筋膜，然后将其移植到体内。将培养的HVFs分为胶原I/III比率高组（n = 6）和低组（n = 4）。高比例组细胞的增殖能力显著高于低比例组（P < 0.05）。用高比值组的HVFs制作等效的筋膜。在随后的动物研究中，在移植后12周，可以追踪到组织良好的含有HVFs的新筋膜形成。我们的研究结果表明，组织工程筋膜可以在体外和体内从HVFs中培养出来，这可能是未来治疗POP的有效方法。
Mesh-augmented reconstructive surgery for pelvic organ prolapse (POP) does not meet clinical expectations. A tissue-engineered fascia equivalent needs to be developed.Human vaginal fibroblasts (HVFs) from 10 patients were characterized in vitro. Eligible HVFs and a biodegradable scaffold were used to fabricate a fascia equivalent, which was then transplanted in vivo.The cultured HVFs were divided into high (n = 6) or low (n = 4) collagen I/III ratio groups. Cells of the high-ratio group exhibited significantly higher proliferation potential than those of the low-ratio group (P < 0.05). A fascia equivalent was made with HVFs of the high-ratio group. In the subsequent animal study, a well-organized neo-fascia formation containing HVFs could be traced up to 12 weeks after transplantation.Our results suggest that a tissue-engineered fascia could be developed from HVFs in vitro and in vivo, which might be an effective treatment for POP in the future.